Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter

• US 8,298,818 B2
• Filed: 04/27/2007
• Issued: 10/30/2012
• Est. Priority Date: 04/28/2006
• Status: Active Grant

• Current Assignee: University of Florida Research Foundation, Incorporated (State University System of Florida)
• Original Assignee: University of Florida Research Foundation, Incorporated (State University System of Florida)
• Inventors: Hauswirth, William W., Byrne, Barry John, Boye, Sanford Leon
• Primary Examiner(s): Wilson, Michael C.
• Application Number:
  US12/298,845
• Publication Number:
  US 20100069467A1
• Time in Patent Office: 2,013 Days
• Field of Search: 424/93.2, 435/320.1, 435/325
• US Class Current: 435/320.1
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2750/14143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2830/15 chimeric enhancer/promoter combination

Abstract

The present inventors concerns vectors carrying a truncated chimeric CMV-chicken β-actin (smCBA) promoter in which the hybrid chicken β-actin/rabbit β-globin intron is greatly shortened, and their use to deliver to an operatively linked polynucleotide to host cells in vitro or in vivo, resulting in expression of the polynucleotide in the host cells. In one embodiment, the vector carrying the smCBA promoter is administered to the eye. In another embodiment, the vector carrying the smCBA promoter is a self-complementary adeno-associated virus (AAV). The AAV vector may be of any serotype (e.g., type 1, type 2, type 3, type 4, type 5, type 6, type 7, type 8, type 9, type 10). In another embodiment, a self-complementary vector carrying the smCBA promoter is administered to the eye. Another aspect of the invention concerns host cells carrying a vector of the invention. Another aspect of the invention concerns pharmaceutical composition comprising the vectors or host cells of the invention, and a pharmaceutically acceptable carrier.

Claims

1. A vector comprising a truncated chimeric CMV-chicken β

-actin promoter, wherein the vector is a self-complementary adeno-associated virus (scAAV), and wherein said truncated chimeric CMV-chicken β

-actin promoter consists of the nucleic acid sequence of SEQ ID NO;

1.

2. The vector of claim 1, further comprising a heterologous polynucleotide operably linked to the truncated chimeric CMV-chicken β

-actin promoter.

3. The vector of claim 2, wherein the heterologous polynucleotide encodes a polypeptide, an interfering RNA molecule or an antisense oligonucleotide.

4. The vector of claim 1, wherein the vector further comprises a polynucleotide encoding a detectable reporter polypeptide.

5. The vector of claim 4, wherein the detectable reporter polypeptide is beta-globin, luciferase, beta-galactosidase, or a fluorescent protein.

6. The vector of claim 5, wherein the fluorescent protein is a green fluorescent protein (GFP).

7. A method of delivering a vector to an isolated cell comprising:

administering the vector of claim 2 to an isolated cell such that the heterologous polynucleotide is expressed in the cell.

8. The method of claim 7, wherein the isolated cell is a human or non-human animal cell.

9. The method of claim 7, wherein the isolated cell is a brain, liver, lung, cardiac, ocular or smooth muscle cell.

10. The method of claim 7, wherein the isolated cell is a neuron.

11. The method of claim 7, wherein the polynucleotide encodes a polypeptide, an interfering RNA molecule or an antisense oligonucleotide.